Skip to main content

Table 2 Multivariate analysis of LC3B globular structures and other clinical pathological parameters that may have a potential role in prognosis. The presence of LC3B globular structures has a strong independent prognostic value (p < 0.001)

From: LC3B globular structures correlate with survival in esophageal adenocarcinoma

 Group 1 patients (neoadjuvant-naïve)Group 2 (neoadjuvant therapy)
 Hazard ratio (95 % CI)p-valueHazard ratio (95 % CI)p-value
LC3B globular structures
 Negative v’s Positive6.086 (3.179–11.653)<0.001*9.136 (2.115–39.462)0.003*
Differentiation
 Mild*1(−)01(−)0
 Moderate0.667 (0.213–2.086)0.4870.0000.976
 Poor0.898 (0.516–1.564)0.7040.677 (0.318–1.441)0.311
Tumor staging
 Stage I*1(−)01(−)0
 Stage II0.627 (0.193–2.029)0.4352.877 (0.323–25.59)0.343
 Stage III-IV0.858 (0.204–3.608)0.8355.043 (0.457–55.67)0.187
Lymphatic mets
 Negative v’s Positive1.632 (0.504–5.288)0.4140.634 (0.196–2.055)0.448
Vascular invasion
 Negative v’s Positive2.304 (1.211–4.384)0.011*0.559 (0.220–1.416)0.220
Neural invasion
 Negative v’s Positive1.050 (0.548–2.009)0.8832.327 (0.876–6.181)0.090